Bioventix logo

BVXP - Bioventix News Story

4050p 20.0  0.5%

Last Trade - 8:48am

Small Cap
Market Cap £209.9m
Enterprise Value £204.1m
Revenue £10.2m
Position in Universe 827th / 1819

Bioventix Plc: Issue of Equity

Wed 8th July, 2020 7:00am
Bioventix plc
(“Bioventix” or the “Company”)

Issue of Equity

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, announces that it has applied for 1,498 ordinary shares
of 5 pence each (the “Option Shares”) to be admitted to trading on AIM
(“Admission”). It is expected that Admission will occur and that dealings
will commence in the Option Shares on 13 July 2020.

The Option Shares are being issued pursuant to an exercise of options by an
employee of the Company. The Option Shares will rank pari passu with the
existing Ordinary Shares.

The total number of Ordinary Shares in issue following Admission will be
5,209,333 and the Company holds no shares in treasury. Therefore, the total
number of Ordinary Shares with voting rights in the Company will be 5,209,333.

The above figure of 5,209,333 may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, Bioventix under
the FCA’s Disclosure Guidance and Transparency Rules.

For further information please contact:

 Bioventix plc Peter Harrison                   Chief Executive Officer  Tel: 01252 728 001  
 finnCap Ltd Geoff Nash/Simon Hicks Alice Lane  Corporate Finance ECM    Tel: 020 7220 0500  

About Bioventix plc:

Bioventix ( specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.

Copyright (c) 2020 PR Newswire Association,LLC. All Rights Reserved
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.